Kaemmerer D, Twrznik M, Kulkarni HR, et al. - Peptide receptor radionuclide therapy (PRRT) is reported to be highly effective in treating locally advanced or metastatic neuroendocrine neoplasms (NENs). Researchers herein compared impact on survival after resection of primary tumors (PTs) after PRRT via retrospectively analyzing data of 889 patients with advanced NEN (G1-G3, stage IV) who received at least 1 cycle of PRRT. In most patients, PT was located in the pancreas (n = 335; 38%) and small intestine (n = 284; 32%). Patients with NENs stage IV showed a significant survival benefit in correlation with undergoing a previous resection of the PT before PRRT.